OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia
Masumeh Hosseininasab, Mehran Zarghami, Shahrzad Mazhari, et al.
Journal of Clinical Psychopharmacology (2020) Vol. 41, Iss. 1, pp. 25-30
Closed Access | Times Cited: 16
Masumeh Hosseininasab, Mehran Zarghami, Shahrzad Mazhari, et al.
Journal of Clinical Psychopharmacology (2020) Vol. 41, Iss. 1, pp. 25-30
Closed Access | Times Cited: 16
Showing 16 citing articles:
Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
Mangala Hegde, Sosmitha Girisa, Bandari BharathwajChetty, et al.
ACS Omega (2023) Vol. 8, Iss. 12, pp. 10713-10746
Open Access | Times Cited: 106
Mangala Hegde, Sosmitha Girisa, Bandari BharathwajChetty, et al.
ACS Omega (2023) Vol. 8, Iss. 12, pp. 10713-10746
Open Access | Times Cited: 106
Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials
Ajaikumar B. Kunnumakkara, Mangala Hegde, Parama Dey, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 4, pp. 447-518
Open Access | Times Cited: 88
Ajaikumar B. Kunnumakkara, Mangala Hegde, Parama Dey, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 4, pp. 447-518
Open Access | Times Cited: 88
Effect of nano‐curcumin on various diseases: A comprehensive review of clinical trials
Shirin Hassanizadeh, Mehrnaz Shojaei, Mohammad Bagherniya, et al.
BioFactors (2023) Vol. 49, Iss. 3, pp. 512-533
Closed Access | Times Cited: 41
Shirin Hassanizadeh, Mehrnaz Shojaei, Mohammad Bagherniya, et al.
BioFactors (2023) Vol. 49, Iss. 3, pp. 512-533
Closed Access | Times Cited: 41
An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders
Nicolás Lamanna‐Rama, Diego Romero‐Miguel, Manuel Desco, et al.
Antioxidants (2022) Vol. 11, Iss. 2, pp. 353-353
Open Access | Times Cited: 24
Nicolás Lamanna‐Rama, Diego Romero‐Miguel, Manuel Desco, et al.
Antioxidants (2022) Vol. 11, Iss. 2, pp. 353-353
Open Access | Times Cited: 24
Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials
Lorenzo Moccia, Francesca Bardi, Maria Benedetta Anesini, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 540-540
Open Access
Lorenzo Moccia, Francesca Bardi, Maria Benedetta Anesini, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 540-540
Open Access
The effects of selected phytochemicals on schizophrenia symptoms: A review
Melika Zamanian, Eric Gumpricht, Sepideh Salehabadi, et al.
Tissue and Cell (2025) Vol. 95, pp. 102911-102911
Closed Access
Melika Zamanian, Eric Gumpricht, Sepideh Salehabadi, et al.
Tissue and Cell (2025) Vol. 95, pp. 102911-102911
Closed Access
Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis
Michele Fornaro, Claudio Caiazza, Martina Billeci, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Michele Fornaro, Claudio Caiazza, Martina Billeci, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis “Nutra NMA SCZ”
Michele Fornaro, Claudio Caiazza, Martina Billeci, et al.
Molecular Psychiatry (2024)
Closed Access | Times Cited: 2
Michele Fornaro, Claudio Caiazza, Martina Billeci, et al.
Molecular Psychiatry (2024)
Closed Access | Times Cited: 2
Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence
Pál Czobor, Brigitta Kakuszi, István Bitter
Schizophrenia Bulletin (2022) Vol. 48, Iss. 6, pp. 1228-1240
Open Access | Times Cited: 10
Pál Czobor, Brigitta Kakuszi, István Bitter
Schizophrenia Bulletin (2022) Vol. 48, Iss. 6, pp. 1228-1240
Open Access | Times Cited: 10
Curcumin and nano‐curcumin applications in psychiatric disorders
Ramin Mohammadzadeh, Marziyeh Fathi, Mohammad M. Pourseif, et al.
Phytotherapy Research (2024) Vol. 38, Iss. 8, pp. 4240-4260
Closed Access | Times Cited: 1
Ramin Mohammadzadeh, Marziyeh Fathi, Mohammad M. Pourseif, et al.
Phytotherapy Research (2024) Vol. 38, Iss. 8, pp. 4240-4260
Closed Access | Times Cited: 1
Schizophrenia, Curcumin and Minimizing Side Effects of Antipsychotic Drugs: Possible Mechanisms
Reyhaneh Rabiee, Saeedeh Hosseini Hooshiar, Amir Ghaderi, et al.
Neurochemical Research (2022) Vol. 48, Iss. 3, pp. 713-724
Closed Access | Times Cited: 7
Reyhaneh Rabiee, Saeedeh Hosseini Hooshiar, Amir Ghaderi, et al.
Neurochemical Research (2022) Vol. 48, Iss. 3, pp. 713-724
Closed Access | Times Cited: 7
Role of Curcumin in the Management of Schizophrenia: A Narrative Review
Damodharan Dinakaran, Vanteemar S. Sreeraj, Ganesan Venkatasubramanian
Indian Journal of Psychological Medicine (2021) Vol. 44, Iss. 2, pp. 107-113
Open Access | Times Cited: 9
Damodharan Dinakaran, Vanteemar S. Sreeraj, Ganesan Venkatasubramanian
Indian Journal of Psychological Medicine (2021) Vol. 44, Iss. 2, pp. 107-113
Open Access | Times Cited: 9
Review: The Chemistry, Toxicity and Antibacterial Activity of Curcumin and Its Analogues
Hannah J. Denison, Sianne Schwikkard, Mouhamad Khoder, et al.
Planta Medica (2023) Vol. 90, Iss. 01, pp. 47-62
Closed Access | Times Cited: 3
Hannah J. Denison, Sianne Schwikkard, Mouhamad Khoder, et al.
Planta Medica (2023) Vol. 90, Iss. 01, pp. 47-62
Closed Access | Times Cited: 3
Effects of curcumin nanodelivery on schizophrenia and glioblastoma
Susana Bulnes, Marina Picó-Gallardo, Harkaitz Bengoetxea, et al.
International review of neurobiology (2023), pp. 163-203
Closed Access | Times Cited: 2
Susana Bulnes, Marina Picó-Gallardo, Harkaitz Bengoetxea, et al.
International review of neurobiology (2023), pp. 163-203
Closed Access | Times Cited: 2
The mitochondria in schizophrenia with 22q11.2 deletion syndrome: From pathogenesis to therapeutic promise of targeted natural drugs
Zongxiang Xiong, Heting Wang, Yutian Qu, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023) Vol. 127, pp. 110831-110831
Closed Access | Times Cited: 2
Zongxiang Xiong, Heting Wang, Yutian Qu, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023) Vol. 127, pp. 110831-110831
Closed Access | Times Cited: 2
Bridging the Gap: Nanotechnology’s Impact on Neuroscience—A Systematic Review of Clinical Trial
Ali Esparham, Samira Roohi, Mehrnaz Gholami, et al.
(2024), pp. 725-737
Closed Access
Ali Esparham, Samira Roohi, Mehrnaz Gholami, et al.
(2024), pp. 725-737
Closed Access
